Industry Newsgene therapyrare diseasekrystal biotechreimbursement
Krystal Biotech Raises Price Target, Reports Revenues
4.8
Krystal Biotech reported fiscal Q4 and full-year 2025 results on Feb. 17, revealing VYJUVEK net product revenues of $107.1 million for Q4 and $389.1 million for the year. On Feb. 25 Guggenheim raised its price target to $284 and reiterated a Buy rating; the company said it has secured over 660 US reimbursement approvals, more than 90 prescriptions in Germany, France and Japan, and $955.9 million in cash.
Key Points
- 1Krystal Biotech reports $107.1M Q4 and $389.1M FY2025 VYJUVEK net revenue.
- 2Secures over 660 US reimbursement approvals, demonstrating broad payer access and commercial traction.
- 3Maintains $955.9M cash, enabling continued commercialization and potential Italy launch in H2 2026.
Scoring Rationale
Solid official financial disclosures and analyst upgrade but limited relevance to core data science audience.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems